Shenzhen READLINE Technology Co., Ltd.

Company Profile

Product Certification&
Enterprise Certification

Country: China (Mainland)

Business Type: Trading Company

Ms.Jessie Huang
Tel: +86-755-26659310
Ms.Yang
Tel: 86-755-26659310
Ms.Eva Chen
International market manager
Tel: 8675526659310-805
Ms.Sisi
Tel: +86-755-26659310

Mobile:18025382833
Tel:+86-755-26659310
Fax:
URL:http://www.szreadline.com
Province/state:Guangdong
City:Shenzhen
Street:A-3rd Floor, Wanhe Medical Park, No. 8, Gaoxin C.1st Ave, Nanshan District, Shenzhen, Guangdong, China.
MaxCard:

About us

Welcome To Our Site!
Shenzhen Readline Biotech Co., Ltd. is an innovative high-tech enterprise with enzymatic catalysis technology as its core and multidisciplinary applications. It is one of the globally leading enterprises committed to apply the directed evolution of enzymes to the large-scale production of characteristic raw materials such as peptides, polysaccharides, and nucleic acids; meanwhile it is actively exploring the application of its products in new fields.

Since founded in 2017, the company has been engaged in R&D and production of characteristic raw materials with high-tech barriers. Numerous products of characteristic polypeptides have been commercialized by the company’s own accumulated technical advantages in enzyme screening and modification (including bioinformatic analysis, molecular biology, enzyme directed evolution and other technologies), enzyme catalysis, solid phase chemistry, liquid phase chemistry, site-specific modification of peptides and molecular building blocks for the synthesis (special amino acids and derivatives, functional saccharides and derivatives, nucleotides and derivatives). The company has formed a multi-technological joint development of enzyme catalysis technology, liquid phase synthesis technology and solid phase synthesis technology (Readline is currently one of the few enterprises with both third-generation and second-generation technologies in the market, and the first one in the polypeptide industry), more than a dozen high added-value functional molecular blocks and characteristic raw materials have already been promoted synchronously in its R&D pipeline.

The company adopts the innovative combined business model of ‘Technology + Operation’, in which the operational team consists of a number of previous executives from listed enterprises and Fortune 500 companies; and the technical team consists of several postdoctoral fellows, university professors, experts in Synthetic Biology, AI technology, Chemistry, Material Science as well as Engineering Science. The company is led by 1 national-level leading talent, 2 local-level leading talents in Shenzhen, 5 senior engineers and 10 intermediate engineers, and the proportion of R&D personnel exceeds 60%. At present, the company has just completed its Series A funding of over 100 million yuan, which will be spent on R&D and the construction of production bases.

The company currently owns one R&D center, three manufacturing bases and two testing centers. The R&D center is located in Shenzhen Nanshan Hi-tech Industrial Park and covers an area of 2,500 square meters, which has been set up and put into use since 2017. The Gansu production base occupies an area of 1,700 square meters, it was built in 2020 and has passed the ISO9001 quality control certificate in the same year. The Shenzhen production base was constructed in accordance to the GMP and covers an area of about 500 square meters, which will be put into production in the first half of 2021. The Zhuhai production base is currently in the design stage and will be completed in construction by 2021, which occupies an area up to 10,000 square meters. The Shenzhen testing center has been in use since 2017, it is presently in progress of upgradation and expansion in accordance with the GMP requirements, which are expected to be completed in the first half of 2021. The Zhuhai testing center is currently in the design stage and will be completed together with the Zhuhai production base in 2021.